Related references
Note: Only part of the references are listed.Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib
Djoeke de Wit et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application
Marina Venzon Antunes et al.
BIOANALYSIS (2015)
Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions
Abraham J. Wilhelm et al.
CLINICAL PHARMACOKINETICS (2014)
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Lucien Noens et al.
HAEMATOLOGICA (2014)
Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer
Sara Capiau et al.
ANALYTICAL CHEMISTRY (2013)
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
Francis J. Giles et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions
Pieter M. M. De Kesel et al.
BIOANALYSIS (2013)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Richard A. Larson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry
Eva Kralj et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2012)
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Amina Haouala et al.
BLOOD (2011)
Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
C. Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
A. Haouala et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls
Peter M. Edelbroek et al.
THERAPEUTIC DRUG MONITORING (2009)
Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis
BK Matuszewski
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
BK Matuszewski et al.
ANALYTICAL CHEMISTRY (2003)
Bioanalytical liquid chromatographic method validation. A review of current practices and procedures
H Rosing et al.
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES (2000)